A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex with Cis-gender Men and/or Transgender Individuals.
HIV Vaccine Study Among 18-60 year-old Sexually Active Men or Transgender Individuals
Sponsor: National Institutes of Health
Enrolling: Male and Female Patients
Study Length: 30 Months
Clinic Visits: 13
IRB Number: AAAS5793
U.S. Govt. ID: NCT03964415
Contact: The Mosaico Study Team: 347-770-2201 / jb2226@columbia.edu
Additional Study Information: Almost 40,000 people get HIV in the U.S. each year and almost all occur via sexual contact, especially male-to-male contact. The number of new infections has decreased slightly each year, however, we need other HIV prevention tools, such as developing a greatly, effective HIV vaccine, to better reduce HIV infections. SCREENING AND EDUCATION: 1. Consent will be obtained prior to screening procedures 2. We will ask you to complete an electronic pre-screen questionnaire to help us determine your eligibility. 3. If eligible, we will ask you to attend a one-on-one educational visit (compensation: $20-25). If you are still interested in joining the study after reviewing the study with a staff member, we will ask about your medical history and draw blood to assess medical eligibility. 4. We will schedule a return visit to review the results of your blood tests. If eligible, we will ask you to review and sign a study-specific consent form and we will schedule you for the first study visit. STUDY PURPOSE AND PARTICIPANT DEMOGRAPHIC SOUGHT: 1. This study aka The Mosaico Study is a phase 3 HIV vaccine study to find out if the study vaccines can effectively prevent HIV among 18-60 year old and HIV-negative transgender people that have sex with cis-gender men and/or with transgender people or, cis-gender men that have sex with cis-gender men or, gender non-conforming people. 2. STUDY DESIGN & COMPENSATION The study consists of 13 visits over 30 months (about 1.5 hours per visit) including: 4 injection visits (placebo or vaccine); These are scheduled every 3 months throughout the first 12 months (2 x $100 + 2 x $150 = $500). 9 blood draw only visits (9 x $50 = $450). BONUSES: $50 for completing ALL 4 injection visits ($50 compensation given at visit 7.0 at month 12, if eligible). $50 at visit 12.0 at month 24 for completing the visit ($50 compensation given at visit 24.0). $100 at "Final Visit" for staying engaged with the study through the end ($100 compensation given at "Final
This study is closed
Investigator
Magdalena Sobieszczyk, MD
Do You Qualify?
Are you between 18 and 60 years old? Yes No
Are you HIV-negative? Yes No
Do you want to begin or continue a PrEP regimen? Yes No
Are you okay with having blood drawn? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.


For more information, please contact:
The Mosaico Study Team
jb2226@columbia.edu
347-770-2201